Cytosorbents (CTSO) Accumulated Expenses (2010 - 2026)

Cytosorbents' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• Quarterly Accumulated Expenses changed 0.39% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (changed 0.39% YoY) and the FY2025 annual result came in at $6.3 million, up 4.43% from the prior year.
• Accumulated Expenses was $6.0 million for Q1 2026 at Cytosorbents, down from $6.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $9.4 million in Q1 2022 and bottomed at $5.5 million in Q3 2024.
• A 5-year average of $6.9 million and a median of $6.6 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses rose 22.84% — and 2023, when it tumbled 32.18%.
• Cytosorbents' Accumulated Expenses stood at $8.0 million in 2022, then fell by 7.43% to $7.4 million in 2023, then dropped by 18.04% to $6.0 million in 2024, then increased by 4.43% to $6.3 million in 2025, then fell by 5.38% to $6.0 million in 2026.
• Business Quant data shows CTSO's Accumulated Expenses at $6.0 million in Q1 2026, $6.3 million in Q4 2025, and $6.6 million in Q3 2025.